Genomic testing refers to the detection of all types of variations in genetic material, including inherited, somatic and epigenetic variations. Performed after your tumor was found and diagnosed, genomic testing may assist your physician to prescribe the optimal therapeutic regimen, specifically tailored for your tumor type and genetic profile. Genetic testing refers to the detection of inherited (germline) variations in genetic material, and it may assist the physician to determine the underlying causes of various disabilities and disorders, and to assess the lifetime risks of certain deleterious diseases, such as certain types of cancer.

Genomic testing identifies the DNA alterations that may be driving the growth of a specific tumor and provides information regarding drug efficacy or adverse effects of drug use (pharmacogenomics). The precise diagnosis of genomic mutations that are unique to your individual cancer may help doctors identify treatments to which your tumor is highly likely to be susceptible.

Currently, you can order our COVID-19 tests here. We will soon update our diagnostic portfolio and will have more tests available for patients worldwide.

The NIFTY test is a non-invasive prenatal test, intended for the detection of several chromosomal aneuploidies (chromosomes 13, 18, 21, and sex chromosomes) and large structural variations (84 types of microdeletionand microduplication syndromes includingDi George Syndrome). The test is assisting your OB\GYN to rule out a set of genetic syndromes that may affect your fetus at a high level of confidence. The test requires a small volume of maternal blood sample and is effective from as early as week 10 of pregnancy. NIFTY offers higher rates of accuracy than traditional screening tests and, unlike invasive procedures such as amniocentesis, poses no miscarriage risk to the mother. To date, over 10 million NIFTY tests have been performed worldwide. For more information, please visit here.